BioCentury | Jun 20, 2020
Translation in Brief

CAR Ts against senescent cells; plus NIH program for ALS, sex-dependent COVID-19 immune responses and more

...small molecules, may conduct proof-of-concept animal studies. Targets IL-15 - Interleukin-15 PLAUR (uPAR) (suPAR) - Plasminogen...
...ligand BioCentury Staff Memorial Sloan Kettering Cancer Center Scripps Research National Institutes of Health University of Amsterdam BridgeBio Pharma Inc. Johns Hopkins University Plasminogen...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

...stroke but one that’s eluded development in any indication. Unlike SOC alteplase, a recombinant tissue plasminogen...
...mortality in the subgroup bolstered its case. Mechanistic studies showed that tPA activates the enzyme plasminogen...
...endovascular intervention population. The company is working on next-generation PSD95 inhibitors that are resistant to plasminogen...
BioCentury | Jun 4, 2019
Financial News

June 4 Financial Quick Takes: Lung Therapeutics' $36M series C; plus Strand, Hansoh, Inhibrx and more

...I trial of non-fibrinolytic peptide LTI-03 in idiopathic pulmonary fibrosis. LTI-01 is a single-chain urokinase plasminogen...
BioCentury | Oct 5, 2018
Company News

BARDA, Genentech partner against influenza, health security threats

...Shionogi retains rights. The drug is approved as Xofluza in Japan. Alteplase is a tissue plasminogen...
BioCentury | Oct 4, 2018
Emerging Company Profile

Banking on exosomes

...biologics guidelines from FDA. ALX-051 is in development for bleeding disorders with antiplasmin and antitissue plasminogen...
BioCentury | Oct 1, 2018
Company News

BARDA, Genentech partner against influenza, health security threats

...Shionogi retains rights. The drug is approved as Xofluza in Japan. Alteplase is a tissue plasminogen...
...unit of Roche (SIX:ROG; OTCQX:RHHBY). Alicia Parker Actilyse, Actilyse Cathflo, Activacin, Activase, Cathflo Activase, GRTPA, alteplase (Tissue plasminogen...
BioCentury | Sep 26, 2018
Distillery Therapeutics

Cancer

...in Phase II testing for pancreatic cancer and preclinical testing for solid tumors. TARGET/MARKER/PATHWAY: Urokinase-type plasminogen...
...Australia email: mkelso@uow.edu.au CONTACT: Marie Ranson, same affiliation as above email: mranson@uow.edu.au Chris Lieu University of Wollongong Urokinase-type plasminogen...
BioCentury | Sep 25, 2018
Preclinical News

Ionis, Rockefeller team find peripheral blood target for Alzheimer's

...light on neuroinflammation's role in AD. The team suggested antisense oligonucleotide depletion of plasmin's precusor, plasminogen...
...disease's other hallmark: β amyloid plaques. Plasmin is the active form of the blood protein plasminogen...
...the National Academy of the Sciences study , the researchers showed an antisense oligonucleotide targeting plasminogen...
BioCentury | Sep 10, 2018
Distillery Techniques

Drug delivery

...animal models of acute cardiovascular or pulmonary disease. Chiesi Farmaceutici S.p.A. markets Retavase, a recombinant plasminogen...
BioCentury | Aug 9, 2018
Distillery Techniques

Drug platforms

...or the combination of chemokine CC motif ligand 5 (RANTES; CCL5), thrombospondin-1 (TSP-1; THBS1) and plasminogen...
...motif ligand 5 (RANTES) (CCL5) Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) Macrophage migration inhibitory factor (MIF) Plasminogen...
Items per page:
1 - 10 of 422